人福医药：玉蚕颗粒进入II期临床试验研究

Core Viewpoint - The announcement indicates that Renfu Pharmaceutical's subsidiary has registered a Phase II clinical trial for a new drug aimed at treating diabetic kidney disease with significant albuminuria, which may provide insights for future Phase III studies [1] Group 1: Clinical Trial Details - The trial is named "Yucan Granules for the Treatment of Diabetic Kidney Disease with Significant Albuminuria: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase II Clinical Trial" [1] - The primary objective of the trial is to preliminarily evaluate the efficacy and safety of Yucan Granules in treating diabetic kidney disease with significant albuminuria and to explore dosage options [1] - The trial results are expected to provide a basis for the subsequent Phase III clinical research [1]